These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 30158831)

  • 1. Innate and Adaptive Cell Populations Driving Inflammation in Dry Eye Disease.
    Reyes JL; Vannan DT; Eksteen B; Avelar IJ; Rodríguez T; González MI; Mendoza AV
    Mediators Inflamm; 2018; 2018():2532314. PubMed ID: 30158831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The core mechanism of dry eye disease is inflammation.
    Wei Y; Asbell PA
    Eye Contact Lens; 2014 Jul; 40(4):248-56. PubMed ID: 25390549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rabbit models of dry eye disease: Current understanding and unmet needs for translational research.
    Singh S; Sharma S; Basu S
    Exp Eye Res; 2021 May; 206():108538. PubMed ID: 33771517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treg-recruiting microspheres prevent inflammation in a murine model of dry eye disease.
    Ratay ML; Glowacki AJ; Balmert SC; Acharya AP; Polat J; Andrews LP; Fedorchak MV; Schuman JS; Vignali DAA; Little SR
    J Control Release; 2017 Jul; 258():208-217. PubMed ID: 28501670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Inflammatories in the Treatment of Dry Eye Disease: A Review.
    Perez VL; Mah FS; Willcox M; Pflugfelder S
    J Ocul Pharmacol Ther; 2023 Mar; 39(2):89-101. PubMed ID: 36796014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options.
    Periman LM; Perez VL; Saban DR; Lin MC; Neri P
    J Ocul Pharmacol Ther; 2020 Apr; 36(3):137-146. PubMed ID: 32175799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic inhibitors for the treatment of dry eye syndrome.
    Rodríguez-Pomar C; Pintor J; Colligris B; Carracedo G
    Expert Opin Pharmacother; 2017 Dec; 18(17):1855-1865. PubMed ID: 29115899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sjogren's syndrome from the perspective of ophthalmology.
    Kuklinski E; Asbell PA
    Clin Immunol; 2017 Sep; 182():55-61. PubMed ID: 28476437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in mesenchymal stem cell-derived extracellular vesicles therapy for Sjogren's syndrome-related dry eye disease.
    Li SJ; Cheng RJ; Wei SX; Xia ZJ; Pu YY; Liu Y
    Exp Eye Res; 2023 Dec; 237():109716. PubMed ID: 37951337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rethinking dry eye disease: a perspective on clinical implications.
    Bron AJ; Tomlinson A; Foulks GN; Pepose JS; Baudouin C; Geerling G; Nichols KK; Lemp MA
    Ocul Surf; 2014 Apr; 12(2 Suppl):S1-31. PubMed ID: 24725379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay.
    Messmer EM; von Lindenfels V; Garbe A; Kampik A
    Ophthalmology; 2016 Nov; 123(11):2300-2308. PubMed ID: 27665213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease.
    Barabino S; Chen Y; Chauhan S; Dana R
    Prog Retin Eye Res; 2012 May; 31(3):271-85. PubMed ID: 22426080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory basis for dry eye disease flares.
    Perez VL; Stern ME; Pflugfelder SC
    Exp Eye Res; 2020 Dec; 201():108294. PubMed ID: 33039458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pathophysiology, diagnosis, and treatment of dry eye disease.
    Messmer EM
    Dtsch Arztebl Int; 2015 Jan; 112(5):71-81; quiz 82. PubMed ID: 25686388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-20 is involved in dry eye disease and is a potential therapeutic target.
    Wang HH; Chen WY; Huang YH; Hsu SM; Tsao YP; Hsu YH; Chang MS
    J Biomed Sci; 2022 Jun; 29(1):36. PubMed ID: 35681232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled release of an HDAC inhibitor for reduction of inflammation in dry eye disease.
    Ratay ML; Balmert SC; Bassin EJ; Little SR
    Acta Biomater; 2018 Apr; 71():261-270. PubMed ID: 29526828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corneal Epithelial Immune Dendritic Cell Alterations in Subtypes of Dry Eye Disease: A Pilot In Vivo Confocal Microscopic Study.
    Kheirkhah A; Rahimi Darabad R; Cruzat A; Hajrasouliha AR; Witkin D; Wong N; Dana R; Hamrah P
    Invest Ophthalmol Vis Sci; 2015 Nov; 56(12):7179-85. PubMed ID: 26540656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study design and baseline findings from the progression of ocular findings (PROOF) natural history study of dry eye.
    McDonnell PJ; Pflugfelder SC; Stern ME; Hardten DR; Conway T; Villanueva L; Hollander DA
    BMC Ophthalmol; 2017 Dec; 17(1):265. PubMed ID: 29284427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting.
    Baudouin C; Irkeç M; Messmer EM; Benítez-Del-Castillo JM; Bonini S; Figueiredo FC; Geerling G; Labetoulle M; Lemp M; Rolando M; Van Setten G; Aragona P;
    Acta Ophthalmol; 2018 Mar; 96(2):111-119. PubMed ID: 28390092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wakayama symposium: interface between innate and adaptive immunity in dry eye disease.
    Na KS; Hwang KY; Lee HS; Chung SH; Mok JW; Joo CK
    BMC Ophthalmol; 2015 Dec; 15 Suppl 1(Suppl 1):159. PubMed ID: 26817830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.